New combo therapy aims to shrink rare melanomas before surgery
NCT ID NCT05546827
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 37 times
Summary
This study is testing whether giving radiation therapy along with immunotherapy before surgery can help people with rare sinonasal or anorectal melanoma. About 40 participants will receive combination immunotherapy (like ipilimumab with nivolumab) followed by radiation, then surgery. The goal is to see if this approach improves the tumor's response before it is removed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SINONASAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ipilimumab and nivolumab or nivolumab and relatlimab (combination immunotherapy)
What this could lead to
If it works, this could lead to a more effective treatment approach for rare mucosal melanomas, potentially improving tumor response before surgery.
What could go wrong
This is a small, early-phase trial with only 40 participants, so results may not apply broadly. The combination of radiation and immunotherapy may cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.